Atenolol is a ß1 receptor specific antagonist, a drug belonging to the group of ß-blockers, a class of drugs used primarily in cardiovascular diseases. Introduced in 1976, atenolol was developed as a replacement for propranolol in the treatment of hypertension. Atenolol (trade name Tenormin) can be used to treat cardiovascular diseases and conditions such as hypertension, coronary heart disease, arrhythmias, angina (chest pain) and to treat and reduce the risk of heart complications following myocardial infarction (heart attack)
A new treatment strategy for hypertension can cut the risk of strokes by around 25 percent and coronary events by around 15 percent according to the preliminary results of a major international trial announced at the American College of Cardiology Late Breaking Clinical Trials II Meeting in Orlando today.
An international trial comparing blood-pressure lowering treatments has been stopped early due to the significantly better performance of one of the treatments in the trial.
A study published in this weeks issue of THE LANCET suggest that atenolol - one of the most widely prescribed beta-blockers for reducing blood pressure - may not be effective in reducing heart attacks or death from cardiovascular causes.
Patients with or at risk for heart disease who take the anti-hypertensive drug clonidine before non-cardiac surgery can significantly reduce the risk of complications and death due to inadequate blood flow to the heart, according to a study by UCSF researchers at the San Francisco Veterans Affairs Medical Center.
Physicians who prescribe the regular use of beta-agonist drugs for asthma could be endangering their patients, two new studies by researchers at Cornell and Stanford universities find.